Pfizer-BioNTech COVID-19 vaccine immune response in the elderly
In the absence of therapeutic intervention, vaccines are the only available avenue to contain the COVID-19 (coronavirus disease 2019) pandemic. Currently, vaccines against the causal agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are being administered globally.
It is essential to understand the vaccine response to know its efficacy under diverse plans and cohorts. The duration of protection imparted by the current vaccine is unknown in a real-world setting. This is important, particularly in underrepresented groups in clinical trials. One such group is the elderly population, aged above 80 years, who are at the most significant risk of death from COVID-19 disease.